NCT06235112NARecruiting

AI Detection of Incidental Coronary Artery Calcium to Enhance Cardiovascular Disease Prevention

Brigham and Women's Hospital

Start Date

7/31/2024

Completion Date

12/1/2027

Summary

AI INFORM is a multicenter randomized trial that will test the hypothesis that providing clinicians information on the presence and amount of coronary artery calcifications (CAC), will result in initiation or intensification of preventive therapies. The study will use a cloud-based artificial intelligence (AI) platform (Nanox.AI) that can analyze non contrast chest CT and estimate the amount of CAC.

Eligibility Criteria

Age Range: 40 years to 75 years

Inclusion Criteria: * Patients aged between 40-75 with prior chest CT within last 3 years Exclusion Criteria: * Prior coronary artery disease * Prior cancer * Other life-limiting condition

Interventions

DEVICE

Electronic health record-based notification of Nanox.AI Coronary Artery Calcification Assessment

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Coronary Artery Disease

Locations

Brigham and Women's Hospital

Boston, Massachusetts 02445

United States

Run studies, or work at a research site?

Corterve helps sites and sponsors reach patients who are looking for trials. It does not determine eligibility and does not promise an enrolment outcome.

For sponsors, CROs and sites

What Corterve sells to organisations, and the anti-kickback constraints it works within.

Services and published prices

Lay summaries for EU CTR Annex V, pre-screen filtration, recruitment-creative regulatory operations, feasibility reporting.

For research sites

One published licence rate, the same for every site, and the fees a site is never charged.